AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M
ByAinvest
Wednesday, Aug 6, 2025 9:08 pm ET1min read
Pacira BioSciences reported Q2 2025 financial results with total revenues of $181.1 million and a net loss of $4.8 million. The company highlighted its progress in advancing its 5×30 growth strategy, expanding market adoption for its flagship product, EXPAREL. Net product sales were $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera°. Pacira achieved an adjusted EBITDA of $54.3 million and non-GAAP net income of $36.0 million.
Pacira BioSciences, Inc. (PCRX) reported its second quarter (Q2) 2025 financial results, showing mixed performance with total revenues of $181.1 million and a net loss of $4.8 million. The company highlighted its progress in advancing its 5×30 growth strategy, expanding market adoption for its flagship product, EXPAREL. Net product sales for EXPAREL were $142.9 million, ZILRETTA sales were $31.3 million, and iovera° sales were $5.6 million. Pacira achieved an adjusted EBITDA of $54.3 million and non-GAAP net income of $36.0 million [1].Pacira's CEO Frank Lee expressed optimism about the company's performance, stating, "We’re entering the second half of the year with strong momentum and a clear focus on further accelerating growth." The company also reported significant milestones, including surpassing 50% enrollment in a Phase 2 study of PCRX-201 for osteoarthritis and securing favorable patent rulings [2].
Pacira entered into a strategic collaboration with Johnson & Johnson MedTech to expand the market reach of ZILRETTA, leveraging its specialized early intervention sales force to co-promote the treatment to existing and new customers. The company also optimized its manufacturing process for EXPAREL, improving gross margins [3].
Despite the mixed financial performance, Pacira's stock experienced a slight decline during regular trading hours but rebounded in aftermarket trading, increasing by 3.53% to $23.75. The company narrowed its full-year revenue guidance to between $730 million and $750 million and raised its gross margin guidance to 78%-80% [1].
References:
[1] https://www.tipranks.com/news/company-announcements/pacira-biosciences-reports-q2-2025-financial-results
[2] https://www.ainvest.com/news/pacira-biosciences-q2-2025-earnings-call-transcript-key-takeaways-2508/
[3] https://www.biospace.com/press-releases/pacira-biosciences-reports-second-quarter-2025-financial-results
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet